Physician Assistant, Medical · New York, NY
NPI
1316194020
Since 2008
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
520 E. 70th St., Starr 341
New York, NY, 10021
Phone (646) 962-2700
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
166 services
Medicare patients, 2024
75
Average age 76
Drug cost, 2024
$6.3M
715 prescriptions
Company payments, 2025
$16K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maureen Thyne was code 99214 (office e&m - established), 84 times for 42 patients. In total Maureen Thyne billed 166 services in 5 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 84 | 42 | $71.85 | $6,035 |
| 99213 Office E&M - Established | Facility | 54 | 37 | $47.94 | $2,589 |
| 38222 Other Organ Systems | Facility | 23 | 21 | $45.61 | $1,049 |
By year: 2022 $12K for 199 services; 2023 $6,211 for 92 services; 2024 $10K for 166 services.
Medicare prescription drug claims, 2024
In 2024, the drug Maureen Thyne prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 221 prescriptions and refills. In total Maureen Thyne wrote 715 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 221 | 221 | 28 | $3.4M |
| Pegasys Peginterferon Alfa-2a | 124 | 124 | 16 | $511K |
| Hydroxyurea Generic | 51 | 81 | 13 | $871 |
| Valacyclovir Valacyclovir Hcl | 38 | 56 | Under 11 | $1,854 |
| Sprycel Dasatinib | 28 | 32 | Under 11 | $434K |
| Levofloxacin Generic | 19 | 19 | Under 11 | $188 |
| Fluconazole Generic | 17 | 17 | Under 11 | $1,366 |
| Scemblix Asciminib Hydrochloride | 16 | 16 | Under 11 | $324K |
| Besremi Ropeginterferon Alfa-2b-Njft | 15 | 15 | Under 11 | $154K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 14 | 27 | Under 11 | $125 |
| Venclexta Venetoclax | 12 | 12 | Under 11 | $171K |
| Iclusig Ponatinib Hcl | 12 | 12 | Under 11 | $253K |
| Zolpidem Tartrate Generic | 11 | 11 | Under 11 | $176 |
| Alprazolam Generic | 11 | 11 | Under 11 | $13.6 |
Brand drugs: 476 claims; generic drugs: 239 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maureen Thyne $16K ($16K in general payments such as food, travel and fees) from 5 companies. The largest payer was Incyte Corporation with $16K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.